Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Hydrocodone Combination Up-scheduling Marches Forward Despite FDA Ambivalence

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA’s Drug Safety and Risk Management Advisory Committee votes 19-10 to move the opioid drugs to the more restrictive Schedule II because their abuse potential is similar to other drugs already that already have the controlled substances designation.


Related Content

Industry Has 45 Days To Implement DEA’s Rescheduling Of Hydrocodone Combo Products
Abuse Reduction Claim In Opioid Label Will Be Difficult To Attain
Hydrocodone Gets Advisory Committee Review, Offering Congress A Scheduling Out


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts